NCT00663026 - Study Evaluating Bapineuzumab In Alzheimer Disease Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Alzheimer Disease

Interventions

DRUG

bapineuzumab

5 mg bapineuzumab subcutaneous injection once per week for 6 months

DRUG

bapineuzumab

10 mg bapineuzumab subcutaneous injection once per week for 6 months

DRUG

placebo

Placebo subcutaneous injection once per week for 6 months

Trial Locations (17)

14620

Pfizer Investigational Site, Rochester

30033

Pfizer Investigational Site, Decatur

30045

Pfizer Investigational Site, Lawrenceville

33009

Pfizer Investigational Site, Hallandale

33407

Pfizer Investigational Site, West Palm Beach

33445

Pfizer Investigational Site, Delray Beach

53705

Pfizer Investigational Site, Madison

67211

Pfizer Investigational Site, Wichita

75214

Pfizer Investigational Site, Dallas

85006

Pfizer Investigational Site, Phoenix

85351

Pfizer Investigational Site, Sun City

90720

Pfizer Investigational Site, Los Alamitos

91316

Pfizer Investigational Site, Encino

92660

Pfizer Investigational Site, Newport Beach

02914

Pfizer Investigational Site, East Providence

02906

Pfizer Investigational Site, Providence

05201

Pfizer Investigational Site, Bennington